Home

Molecular Screening and Therapeutics (MoST) study

The MoST study uses the power of genomic technology to characterise molecular changes in a patient's cancer that may help to identify a targeted therapy.

MoST has a number of different screening populations

Our program — covers all different types of cancers:

Leukaemia and lymphoma subprogram (MoST-LLy) – Open for screening – for more information see MoST-LLY at QIMR Berghofer

  • for patients with advanced blood cancers without an established therapeutic option.

Pan cancer subprogram (MoST and AYA-MoST) – Closed to new recruitment – see CaSP to refer patients for molecular screening

  • for patients, including Adolescents and Young Adults (AYA), with pathologically-confirmed advanced or metastatic solid cancers of any histological type, either during or after their last line of effective therapy.

Lung cancer subprogram (ASPiRATION) –Closed to new recruitment – see CaSP to refer patients for molecular screening

  • for adults with newly diagnosed, pathologically-confirmed metastatic non-squamous non-small cell lung cancer (NSCLC), with sufficient and accessible tissue for molecular screening.

 

MoST clinical trials

We are using the power of genomic technology to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy.

Read more about MoST clinical trials

ASPiRATION

An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients.

Read more about ASPiRATION

MoST-LLy

A clinical trial research program offering Australians with blood cancer genomic screening and potential access to precision medicines.

Read more about MoST-LLy

MoST has two stages

Stage 1
We use genomic profiling to analyse the molecular characteristics of a patient’s tumour, we gather as much genetic and clinical information as we can to help us identify specific characteristics about the tumour.

A team of experts review the molecular profile of the tumour with other clinical and patient information. A report is provided to the referring clinician.

Stage 2
Patients identified as possessing any of a range of molecular characteristics (identified during Stage 1) may be eligible to access treatment in a MoST therapeutic study (a clinical trial) or other targeted therapy.

Who can participate in MoST?

Pan cancer subprogram: Patients aged 16 years and older with an advanced and/or metastatic solid or blood cancer with limited treatment options, and who are willing and fit enough to participate in a clinical trial, are eligible.

Lung cancer subprogram: Patients aged 18 years and older with newly diagnosed metastatic non-squamous non-small cell lung cancer (NSCLC), who have not had any previous treatment for the lung cancer and who are willing and fit enough to participate in a clinical trial, are eligible.

Your treating oncologist will assess your eligibility, complete the MoST referral forms, and provide all relevant information.

What does participation involve?

For patients

  • Discussing the study with the MoST team (either by telephone or face-to-face)
  • Consenting to the access of samples held by pathology centres
  • Consenting to the access of their medical records
  • Donating a blood sample
  • Completing questionnaires
  • Providing optional consent for access to Medicare/PBS data

Interested in knowing more?

Get in touch